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Background: The population of perinatally HIV-infected adolescents (PHA) continues to expand globally. This study aims to describe the geographic and 
temporal characteristics and outcomes of PHA.  
Methods: Through the Collaborative Initiative for Paediatric HIV Education and Research (CIPHER), individual retrospective data from 12 cohort networks 
were pooled. Included PHA entered care before age 10 years with no known non-vertical route of HIV infection, and followed beyond age 10 years. This 
initial analysis describes characteristics at first visit, start of antiretroviral therapy (ART), start of adolescence (age 10 years) and surviving patients at last 
follow-up. 
Results: Of 37,614 PHA included, 49.4% (18,591) were male and 79% were from sub-Saharan Africa (Table 1). Median (interquartile range [IQR]) follow-up 
during adolescence was 2.36 (1.00-4.35) years, ranging from 2.04 (0.87-3.77, sub-Saharan Africa) to 6.38 (3.51-8.01, Europe & Central Asia) years. 90.7% 
(34,132) of PHA received ART; 9.9% (3,385) started after age 10 years.  Age, CD4 count, CD4 percent and HIV viral load at first visit and ART start varied 
markedly across regions (Table 2). Although laboratory markers improved by age 10 years, median weight-for-age (WAZ), height-for-age (HAZ) and body 
mass index-for-age (BMIZ) WHO Z-scores changed little. Median HAZ at age 10 years and last visit remained well below zero in all regions, although BMIZ 
was less impaired. Reported mortality between age 10 and 15 years was 3.08% (95%CI 2.83-3.36) ranging from 0.78% in Europe & Central Asia to 4.72% in 
South America & Caribbean (Table 1). 
Conclusion: Reported mortality during adolescence was <5% in all regions represented in this global analysis of HIV-infected children surviving to age 10 
years. Under-ascertainment of mortality and impaired growth are concerns. 
 
 
 
 
 
Table 1: Countries represented, periods of observation, duration of follow-up during adolescence and cumulative mortality between 10 and 15 years of age 
of perinatally HIV-infected adolescents by region (N=37,614) 
Region Countries included N (%) Observation 
Period 
Duration of follow-up 
during adolescence – 
median (IQR) years 
Cumulative Mortality  
% (95% CI) 
South & Southeast 
Asia  
Cambodia, India, Indonesia, Malaysia, Myanmar, 
Thailand, Vietnam 
2,902 (7.7) 1994-2014 2.53 (1.17; 4.37) 2.98 (2.08; 4.25) 
Europe & Central 
Asia 
Belgium, France, Ireland, Italy, Netherlands, 
Poland, Portugal, Romania, Russian Federation, 
Spain, Sweden, Switzerland, Ukraine, United 
Kingdom 
3,058 (8.1) 1982-2015 6.36 (3.51; 8.01) 0.78 (0.50; 1.21) 
South America & 
Caribbean 
Argentina, Brazil, Haiti, Honduras  903 (2.4) 1990-2015 4.92 (2.68; 7.37) 4.72 (3.33; 6.65) 
North America United States of America 1,048 (2.8) 1991-2014 3.73 (2.01; 5.43) 1.09 (0.52; 2,24) 
Sub-Saharan Africa Benin, Botswana, Burkina Faso, Burundi, 
Cameroon, Central African Republic, Democratic 
Republic of Congo, Côte d’Ivoire, Ethiopia, Ghana, 
Guinea, Kenya, Lesotho, Malawi, Mozambique, 
Rwanda, Senegal, South Africa, Swaziland, 
Tanzania, Togo, Uganda, Zambia, Zimbabwe 
29,703 
(79.0) 
1996-2015 2.04 (0.87; 3.77) 3.59 (3.26; 3.96) 
 
 
 
 
Table 2: Age, laboratory and anthropometric characteristics of perinatally HIV-infected adolescents (N=37,614) and ranges of medians across regions  
 First Visit ART Start Age 10 Years (+/- 6 months) Last Visit 
 Total 
Median (IQR) 
Min & max 
region medians 
Total 
Median (IQR) 
Min & max 
region medians 
Total 
Median (IQR) 
Min & max 
region medians 
Total 
Median (IQR) 
Min & max 
region medians 
N 37,614  34,132  37,614  36,872  
Age in years 6.7 (4.4; 8.4) 0.7; 7.1 7.4 (5.1; 9.1) 1.0; 7.8 NA NA 12.4 (11.0; 14.4) 12.0; 16.4 
CD4 count in 
cells/mm3 
430 (205; 761) 
N=19388 
255.5; 1282 330 (171; 598) 
N=19368 
221; 1134 686 (446; 972) 
N=26282 
639; 797 688 (465; 948) 
N=31230 
578; 744 
CD4 % 16 (9; 25) 
N=13422 
10; 30 14 (8; 20) 
N=14564 
10; 28 28 (20; 34) 
N=18029 
26; 33 29 (21 ; 35) 
N=23249 
27; 32 
Log10 HIV viral 
load 
5.00 (4.35; 5.58) 
N=4137 
4.96; 5.28 4.94 (4.16; 5.51) 
N=6167 
4.83; 5.10 2.42 (1.69; 3.35) 
N=10155 
1.69; 2.60 2.30 (1.60; 3.18) 
 N=14006  
1.59; 2.60 
WAZ 
 (< age 10 years) 
-1.79 (-2.81; -0.90) 
N=21,037 
-2.71; -0.51 -1.70 (-2.70; -0.83) 
N=22,908 
-2.89; -0.41 -1.42 (-2.18; -0.59) 
N=30,705 
-1.93; 0.09 NA NA 
HAZ (all ages) -1.92 (-2.91; -0.97) 
N=20,013 
-2.37; -0.77 -1.98 (-2.94; -1.05) 
N=19,801 
-2.44; -0.78 -1.54 (-2.36; -0.72) 
N=26,645 
-1.91; -0.32 -1.60 ( -2.46; -0.73) 
N=32,386 
-1.78; -0.34 
BMIZ 
 (> age 5 years) 
-0.60 (-1.54; 0.22) 
N=19892 
-1.44; 0.16 -0.56 (-1.46; 0.25) 
N=19,697 
-1.46; 0.20 -0.54 (-1.26; 0.13) 
N=26,530 
-1.00; 0.38 -0.68 ( -1.46; 0.09) 
N=32,295 
-1.02; 0.50 
 
